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Summary
Background Epidemiological studies suggest that hookworm infection protects against
asthma, and therefore that hookworm infection may have a direct or an indirect therapeutic
potential in this disease. We now report the ﬁrst clinical trial of experimental hookworm
infection in people with allergic asthma.
Objectives To determine the effects of experimental hookworm infection in asthma.
Methods Thirty-two individuals with asthma and measurable airway responsiveness to
adenosine monophosphate (AMP) were randomized and double blinded to cutaneous
administration of either ten Necator americanus larvae, or histamine solution (placebo), and
followed for 16 weeks. The primary outcome was the change in provocation dose of inhaled
AMP required to reduce forced expiratory volume in 1s by 20% (PD20AMP) from baseline to
week 16. Secondary outcomes included change in several measures of asthma control and
allergen skin sensitivity and the occurrence of adverse effects.
Results Mean PD20AMP improved in both groups, more in the hookworm [1.49 doubling
doses (DD)] than the placebo group (0.98DD), but the difference between groups was not
signiﬁcant (0.51DD; 95% conﬁdence interval:  1.79 to 2.80; P=0.65). There were no
signiﬁcant differences between the two groups for other measures of asthma control or
allergen skin sensitization. Infection was generally well tolerated.
Conclusions Experimental infection with ten hookworm larvae in asthma did not result
in signiﬁcant improvement in bronchial responsiveness or other measures of asthma control
in this study. However, infection was well tolerated and resulted in a non-signiﬁcant
improvement in airway responsiveness, indicating that further studies that mimic more
closely natural infection are feasible and should be undertaken.
Keywords airway responsiveness, asthma, helminth, hookworm, intervention, Necator
americanus, randomized-controlled trial
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Introduction
Asthma is one of the commonest chronic diseases of
developed countries, but despite signiﬁcant investment,
research into the aetiology of asthma has yet to identify
the major avoidable causes, and the available treatments
remain poorly effectivein around 10% ofpatients [1]. New
approaches to the prevention and treatment of asthma are
urgently needed. There is now substantial epidemiological
evidence that intestinal parasite infection in general, and
hookworm infection in particular, may protect against
wheeze, asthma and other allergic disease [2, 3]. These
ﬁndings raise the possibility that experimentally induced
parasite infections may be able to contribute, directly or
indirectly, to the development of new strategies for the
management of asthma.
We have previously reported two studies carried out in
preparation for clinical trials of the effect of experimental
hookworm infection in asthma. Theﬁrst was a dose-ranging
study in normal volunteers [4], which found that infection
with ten Necator americanus larvae established a level of
intensity of infection (450eggs/g feces), as identiﬁed in
our previous epidemiological work, to be strongly asso-
ciated with protection against asthma symptoms [5]. The
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junctivitis and measurable airway responsiveness but not
clinically diagnosed asthma, which established that the lung
migration phase of experimental hookworm infection was
well tolerated and did not signiﬁcantly exacerbate airway
responsiveness [6]. This study also showed that an immu-
nological phenotype was induced, which corresponded in
many ways to that seen in natural infection [7], supporting
the use of iatrogenic infection in a therapeutic context. We
now report the ﬁrst randomized double-blind placebo-
controlled study of the effects of experimental hookworm
infection in people with asthma.
Methods
Participants
Potential participants aged 18 years and over with a
physician’s diagnosis of asthma treated with daily inhaled
corticosteroids of up to 1000mcg beclometasone (or
equivalent) were identiﬁed by local advertisement, sent an
information sheet and invited to attend a screening visit.
At the screening visit, after excluding those with
signiﬁcant medical problems (other than asthma) and
women who were pregnant or pre-menopausal and un-
willing to use contraception for the duration of the study,
written informed consent was requested from all partici-
pants. In those who consented, lung function was mea-
sured according to international guidelines [8] using a
Spirometer (Vitalograph, Buckingham, UK) taking the
forced expiratory volume in 1s (FEV1) as the higher of
two values within 100mL. Bronchial hyperresponsiveness
(BHR) was measured by adenosine monophosphate (AMP)
challenge giving sequential inhalations in doubling incre-
ments from 0.115 to 944mM at 2min intervals until FEV1
fell by at least 20% from post-saline baseline or until the
maximum dose of AMP had been inhaled, as described
previously [6]. The AMP dose required to reduce FEV1 by
20% (PD20AMP) was estimated by an interpolation be-
tween the two last doses on the log dose-response plot [8].
Venous blood was collected for haemoglobin estimation,
differential white cell counting and serum albumin. Aller-
gen skin sensitization to Dermatophagoides pteronyssi-
nus, cat fur, grass pollen and positive (histamine) and
negative (saline) controls (Diagenics Ltd, Milton Keynes,
UK) was measured using standard skin prick test methods
defining a positive result as a mean weal diameter 3mm
greater than the negative control [9]. Urine analysis for b-
HCG (QuickVue, Quidel Corporation, San Diego, CA, USA)
was used to confirm that female participants were not
pregnant. An interviewer-administered Juniper Asthma
Quality of Life Questionnaire (AQLQ) based on partici-
pants’ experiences over the preceding fortnight was com-
pleted [10]. Participants were not eligible if their FEV1 fell
by o20% during the bronchial challenge, haemoglobin
was below normal reference levels or they did not have a
positive skin test response to at least one allergen.
All eligible participants had their inhaler technique
reviewed and were provided with a miniWright peak ﬂow
meter (EU scale). Instruction on peak expiratory ﬂow (PEF)
measurement was given and inhaler technique was opti-
mized.Forthedurationofthestudy,participantswereasked
to continue their usual asthma medication and to use short-
acting inhaled b2-agonists for a relief of asthma symptoms.
Randomization
Participants were seen after a 2-week run-in period for
concealed randomization to active or placebo infection,
allocated in blocks of four according to a computer-
generated random code. Larvae were obtained by a culture
of fecal material from a healthy human source known to
be negative for hepatitis B and C and human immunode-
ﬁciency virus, as described previously [11]. Two hundred
microlitres of water containing ten N. americanus larvae
(active infection) or 200mL histamine dihydrochloride
solution (1.7mg/mL) (placebo) was then administered to
an area of skin on the forearm and covered with gauze and
water-tight adhesive dressing for 24h. To ensure the
clinical researcher carrying out the protocol measures
remained blind to treatment allocation, infection solu-
tions were administered by an independent member of the
research team not involved in the study measurements.
Follow-up
After randomization, participants attended study visits
every fortnight for 8 weeks, and at 12 and 16 weeks. Our
original protocol speciﬁed 12 weeks follow-up, but be-
cause the eosinophilia we observed in the safety study was
still decreasing at 12 weeks [6] before commencing the
present study, we elected to increase follow-up to 16
weeks. At each study visit, the Juniper AQLQ was com-
pleted, venous blood was taken for the same tests as at the
screening visit and a stool sample, collected within the
preceding 24h, was provided for quantiﬁcation of egg
burden, as described previously [4]. PD20AMP was mea-
sured, and if after enrolment in the study, participants no
longer responded with a 20% reduction in FEV1 at below
the maximumadministered dose ofAMP,a censored value
of 1888mM was assigned, which is one doubling dose
higher than the maximum dose of AMP administered [12,
13]. An additional full blood count test was carried out 3
weeks after randomization to coincide with the expected
time of onset of hookworm-associated eosinophilia [4, 6].
For the duration of the study, including the 2-week run-in
period before randomization, participants completed a
daily diary, recording twice-daily PEF (best of three
attempts), twice-daily asthma symptom scores on a scale
of 0 (no symptoms) to 5 (maximal symptoms), use of
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mined symptoms potentially attributable to hookworm
infection on a scale from 0 (none) to 10 (maximum possible
severity). Allergen skin tests were repeated at the ﬁnal
visit (week 16) and participants were then unblinded by
the researcher who administered the infection or placebo at
their randomization visit. Those in the hookworm group
were supplied with mebendazole 100mg twice a day for
3 days to eradicate the infection; stool egg counts and blood
eosinophil counts were checked fortnightly in those com-
pleting therapy until egg counts were zero and eosinophils
h a dr e t u r n e dt ow i t h i n0 . 2  10
9/L of their screening value.
Safety and Ethics
Data on adverse effects and haemoglobin, eosinophil and
serum albumin levels were monitored regularly by the
trial statistician and a data monitoring committee. The
study was approved by the Nottingham Research Ethics
Committee, the Research and Development Department at
Nottingham University Hospitals NHS Trust and registered
with the Clinical Trials register (reference NCT00469989).
Data analysis
The primary outcome was the change in PD20AMP from
baseline (mean of screening and randomization visit
values) to the week 16 (ﬁnal visit) value expressed in
doubling doses. Secondary outcome measures of asthma
control were determined for each 2-week period of the
study and comprised PEF variability (two-lowest percent
mean [14]), percentage of symptom-free days and nights
(determined using the twice daily asthma-control symp-
toms scores), and percentage of reliever inhaler-free days
and nights and Juniper AQLQ scores [10]. We plotted these
variables over time to assess any trend, and then com-
puted the difference betweenbaseline (run-inperiod or for
Juniper AQLQ, the mean of the screening and randomiza-
tion visits) and the end of the study (weeks 15 and 16).
We also computed area under the curve (AUC) (GraphPad
Prism 5, GraphPad Software Inc., San Diego, CA, USA)
using the period weeks 5–16 as an alternative summary
variable for PD20AMPand each asthma control measure to
ensure that we did not miss an effect if the measurements
taken at the end of the study had been spurious. Change in
allergen skin sensitization (mm) was calculated as the
difference between the baseline and week-16 saline-
adjusted results. Mean daily symptom scores for adverse
effects potentially attributable to the hookworm infection
were compared over the entire 16 weeks and also for
a pre-determined ‘high-risk’ period chosen, observed as
the period during which the symptoms were most likely to
occur in our previous studies [4, 6].
The two groups were compared using the independent
samples t-test for all variables with the exception of the
adverse effects symptoms and AUC variables, which were
not normally distributed, could not be transformed and were
therefore compared using the Mann–Whitney U-test. As this
was a relatively small trial, we explored whether adjusting
for potential confounders (variables listed in Table 1) using
multiple linear regression affected the results. We repeated
the analyses using data from just the ﬁrst 4 weeks after
randomization to determine whether there was evidence of
exacerbation of asthma during the phase of larval pulmon-
ary migration.
Three sensitivity analyses for each outcome were also
performed excluding participants who: (i) breached the
protocol, (ii) had o75% of potentially available data
complete for the outcome variable and (iii) were infected
with hookworm but did not have a positive stool culture
for larvae at week 16. All data were analysed using STATA
10 SE (STATA Corp., College station, TX, USA).
Sample size calculation
Our pre-study sample size calculation revealed a sample
size of 30 (15 in each group) would provide 80% power to
detect one doubling dose difference in our primary out-
come, change in PD20AMP, between hookworm and
placebo groups assuming a standard deviation of approxi-
mately one doubling dose (DD).
Table 1. Baseline characteristics of participants completing the study
Hookworm (n=16) Placebo (n=16)
Demographics
Gender
Male 8 (50%) 9 (56%)
Female 8 (50%) 7 (44%)
Age (years)
Mean (SD) 40.9 (10.7) 39.8 (15.2)
Body mass index (kg/m
2)
Median (IQR) 25.6 (23.5, 26.8) 26.9 (23.8, 29.6)
Deprivation score
Median (IQR) 15.6 (9.0, 28.3) 13.3 (7.0, 30.3)
Smoking status
Never 10 (63%) 11 (69%)
Ever 6 (38%) 5 (31%)
Asthma medication
Daily inhaled corticosteroid dose
o500mcg/day 10 (63%) 9 (56%)
4=500mcg/day 6 (38%) 7 (44%)
Past oral steroid usage
No 8 (50%) 4 (25%)
Yes – not in last 2 years 5 (31%) 8 (50%)
Yes – in last 2 years 3 (19%) 4 (25%)
Daily long-acting b2-agonist usage
None 11 (69%) 9 (56%)
Some 5 (31%) 7 (44%)
Using index of multiple deprivations [15].
IQR, interquartile range; SD, standard deviation.
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Thirty-four participants were recruited between December
2006 and June 2007 with 17 allocated to each intervention.
Two participants withdrew before our primary end-point
could be measured, that is, before parasite maturation was
complete (one from the placebo group on day 6 due to
psychological problems, and one from the hookworm group
on day 34 due to abdominal pain); they were excluded from
further analysis (Fig. 1). Baseline characteristics of the two
study groups were similar with respect to gender, age, body
mass index, smoking history, index of multiple deprivation
[15], use of asthma medication (Table 1), bronchial respon-
siveness (PD20AMP), lung function (percentage predicted
FEV1 and PEF variability), Juniper AQLQ score and symp-
tom-free and reliever-inhaler-free days and nights (Table 2).
Primary outcome
PD20AMP improved relative to baseline in 11 of the 16
participants ﬁnishing the study who received hookworm
(69%) and in eight who received placebo (50%). Mean
PD20AMP improved in the hookworm group by 1.49 (SD
2.00) DD and in the placebo group by 0.98 (4.02) DD, but
the mean difference between these changes was not
statistically signiﬁcant [0.51DD; 95% conﬁdence interval
(CI)  1.79 to 2.80; P=0.65, Table 3].
Secondary outcomes
Juniper AQLQ and self-reported asthma symptom-free
days and nights scores improved in both groups, more in
the placebo group than the hookworm group (change in
Juniper scores 15.34 vs. 10.66;symptom-free days 13.31%
vs. 8.29%; symptom-free nights 12.63% vs. 9.71%), but
neither this nor any other secondary outcome change
differed signiﬁcantly between groups (Table 3).
For both primary and secondary outcomes, there were
no signiﬁcant differences between the groups when we
adjusted for potential confounders, carried out the sensi-
tivity analyses or when outcomes were assessed using
AUC (weeks 5–16) instead of change from the beginning
to the end of the study (data not shown).
Adverse effects
Localized skin redness and itching at the site of infection
were reported in the hookworm group, particularly be-
tween 1 and 21 days after infection. Median daily scores of
gastrointestinal symptoms were generally low but tended
to be slightly higher in the hookworm than placebo group,
signiﬁcantly so for abdominal pain, and additionally for
loss of appetite and nausea during the high-risk period
(days 29–112; Table 4). There was no evidence to suggest a
worsening of asthma during the ﬁrst 4 weeks of the study.
No clinically important change was observed in either of
the groups in haemoglobin or serum albumen.
Conﬁrmation of hookworm infection
All participants who received hookworm infection had a
rise in peripheral blood eosinophil counts beginning
around day 21 and peaking at 1.4–8.5 10
9/L between
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Fig. 1. Flow chart of study participants.
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Hookworm (n=16) Placebo (n=16)
Lung function [mean (SD)]
% predicted FEV1 at screening visit 83.38 (15.77) 87.06 (23.13)
% predicted FEV1 at randomization 80.25 (17.98) 85.94 (18.37)
Bronchial responsiveness [median (IQR)]
PD20 AMP at screening visit 2.34 (0.78, 7.30) 3.76 (1.49, 7.52)
PD20 AMP at randomization 4.10 (1.53, 11.26)
w 6.98 (1.93, 17.22)
Skin sensitization to allergen at the screening visit [weal size in mm; (mean (SD)]
Grass 5.13 (3.00) 5.31 (5.22)
Cat fur 4.25 (2.58) 3.91 (3.72)
Dermatophagoides pteronyssinus 6.53 (3.29) 6.38 (4.36)
Juniper AQLQ scores
z [median (IQR)]
Juniper score at screening visit for run-in period 193.00 (186.00, 212.50) 175.00 (154.00, 203.00)
Juniper score at randomization for run-in period 200.00 (186.50, 212.00) 186.50 (174.00, 209.00)
PEF variability
‰ [median (IQR)]
PEF variability (%) during run-in period 91.99 (87.96, 93.10) 91.68 (85.62, 94.25)
% symptom-free days/nights [median (IQR)]
% symptom-free days during run-in period 66.07 (21.43, 88.31) 46.43 (8.12, 96.43)
% symptom-free nights during run-in period 66.76 (40.66, 95.83) 85.71 (57.69, 92.58)
% reliever-inhaler-free days/nights [median (IQR)]
% reliever-free days during run-in period 84.52 (7.42, 92.26) 60.71 (3.57, 92.86)
% reliever-free nights during run-in period 75.65 (44.78, 100.00) 92.86 (76.92, 100.00)
n=13.
wn=15.
zMaxiumum score of 224 where the higher scores indicates better quality of life.
‰% PEF variability: a value of 100 indicates no variability, i.e. perfect control.
% predicted FEV1, percentage predicted forced expiratory volume in 1s; AQLQ, Asthma Quality of Life Questionnaire; IQR, inter-quartile range;
PD20AMP (DD), provocation dose of adenosine monophosphate to reduce forced expiratory volume in 1s by 20% in doubling doses; PEF, peak
expiratory ﬂow; SD, standard deviation.
Table 3. Change in asthma and allergic outcomes from the baseline to the end of the study
Mean (SD)
Difference
in means 95% CI
P-
value
Hookworm
(n=16)
Placebo
(n=16)
Bronchial responsiveness (DD)
Change in PD20AMP (DD) (ﬁnal visit – mean of randomization and screening visits) 1.49 (2.00) 0.98 (4.02) 0.51  1.79, 2.80 0.65
Skin sensitivity (mm)
Change in skin sensitization to grass (ﬁnal visit – screening visit)  0.59 (2.42)  0.19 (2.37)  0.41  2.14, 1.32 0.63
Change in skin sensitization to cat fur (ﬁnal visit – screening visit) 0.19 (1.74) 0.03 (1.63) 0.16  1.06, 1.37 0.79
Change in skin sensitization to Dermatophagoidespteronyssinus(ﬁnal visit–screening visit)  0.66 (1.46)  0.19 (2.45)  0.47  1.94, 1.00 0.52
Juniper AQLQ scores
w
Change in Juniper score (ﬁnal visit – mean of screening and randomization visits) 10.66 (14.08) 15.34 (22.41)  4.69  18.20, 8.82 0.48
PEF variability
z
Change in PEF variability (%) (ﬁnal 2 weeks – run-in period) 1.03 (6.17)  1.21 (7.17) 2.23  2.60, 7.06 0.35
% symptom-free days/nights
Change in % symptom-free days (ﬁnal 2 weeks – run-in period) 8.43 (39.67) 12.59 (46.39)  4.16  35.32, 27.01 0.79
Change in % symptom-free nights (ﬁnal 2 weeks – run-in period) 9.05 (32.50) 12.72 (48.98)  3.66  33.68, 26.35 0.80
% reliever free days/nights
Change in % reliever-free days (ﬁnal 2 weeks – run-in period) 0.37 (24.87) 1.39 (34.46)  1.03  22.72, 20.67 0.92
Change in % reliever-free nights (ﬁnal 2 weeks – run-in period)  0.01 (21.49) 3.59 (27.17)  3.60  21.28, 14.09 0.68
P-value for independent samples t-test.
wHigher scores indicate best the quality of life.
z% PEF variability value of 100 indicates no variability, i.e. perfect control.
95% CI, 95% conﬁdence interval; AQLQ, Asthma Quality of Life Questionnaire; DD, doubling dose; PEF, peak expiratory ﬂow; PD20AMP (DD),
provocation dose of adenosine monophosphate to reduce forced expiratory volume in 1s by 20% in doubling doses; SD, standard deviation.
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Hookworm as therapy for asthma 303days 42 and 84. Eosinophil counts in the hookworm group
were all higher at the end of the study than at the time of
infection (Fig. 2). Nine of the 16 participants who received
hookworm and completed the study had eggs detected in
their stool samples, appearing by week 6 in three and week
8 in six participants. At the ﬁnal visit, stool cultures were
positive for nine participants, eight of whom had had
detectable eggs in their stool samples previously. All
positive egg counts at this ﬁnal visit were between 95
and 213eggs/g feces.
Assessment of participant blinding
At the end of the study, 11 participants in the hookworm
group thought correctly that they had received infection
(due to visible portals of entry on the skin and gastro-
intestinal disturbance); ﬁve did not know. Of those who
received the placebo, eight correctly thought they had
been allocated the placebo, two incorrectly thought they
had received hookworm and six did not know. Thirteen
out of 16 participants who received hookworm and
completed the study elected to keep their infection.
Discussion
This is the ﬁrst reported intervention study of experimental
hookworm infection in people with asthma. We found that
the infection improved BHR by half a doubling dose more
than the placebo group, although the conﬁdence interval
was wide and the difference between the groups was not
signiﬁcant. Our ﬁndings provide proof of concept that trials
of experimental hookworm infection are feasible, well
Table 4. Symptoms potentially attributable to hookworm infection experienced during the 16-week study period and high-risk period for participants
with and without infection
Symptoms
Daily score (scale 0–10) over total 16-week period Daily score (scale 0–10) over high risk period
z
Hookworm
Median (range)
Placebo
Median (range)
Difference
in medians P-value
w
Hookworm
Median (range)
Placebo
Median (range)
Difference
in medians P-value
w
Localized skin itching 0.28 (0.04, 2.17) 0 (0, 0.16) 0.28 o0.001 1.40 (0.24,4.43) 0 (0, 0.67) 1.40 o0.001
Localized skin redness 0.45 (0.06, 2.13) 0 (0, 0.23) 0.45 o0.001 2.18 (0.33,4.19) 0 (0, 1.19) 2.18 o0.001
Nausea 0.08 (0, 1.51) 0.01 (0, 0.46) 0.07 0.17 0.05 (0, 1.84) 0 (0, 0.61) 0.05 0.04
Diarrhoea 0.06 (0, 2.03) 0.06 (0, 0.52) 0.00 0.69 0.04 (0, 1.90) 0.05 (0, 0.29)  0.01 0.85
Abdominal pain 0.23 (0, 2.05) 0.03 (0, 1.04) 0.20 0.02 0.30 (0, 2.59) 0.01 (0, 0.92) 0.29 0.02
Flatulence 0.24 (0, 5.43) 0.12 (0, 1.65) 0.12 0.25 0.20 (0, 6.07) 0.05 (0, 1.77) 0.15 0.23
Indigestion 0.11 (0, 2.56) 0.01 (0, 0.43) 0.10 0.31 0.07 (0, 3.03) 0 (0, 0.67) 0.07 0.24
Loss of appetite 0.08 (0, 0.42) 0 (0, 1.18) 0.08 0.08 0.08 (0, 0.38) 0 (0, 0.83) 0.08 0.04
Tiredness 0.18 (0, 4.47) 0.67 (0, 5.00)  0.49 0.51 0.20 (0, 5.10) 0.36 (0, 5.52)  0.16 0.52
zHigh-risk periods: localized skin symptoms (days 1–21), gastrointestinal symptoms and tiredness (days 29–112).
P-value o0.05.
wP-value for Mann–Whitney-U-test.
Days after randomization
E
o
s
i
n
o
p
h
i
l
 
c
o
u
n
t
 
(
b
i
l
l
i
o
n
/
l
i
t
r
e
)
10.0
(a) (b)
8.0
6.0
4.0
2.0
0.0
Days after randomization
E
o
s
i
n
o
p
h
i
l
 
c
o
u
n
t
s
 
(
b
i
l
l
i
o
n
/
l
i
t
r
e
)
10.0
8.0
6.0
4.0
2.0
0.0
Fig. 2. Peripheral blood eosinophil counts in participants randomized to (a) hookworm and (b) placebo.
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304 J. R. Feary et altolerated and, because the majority of participants chose to
retain their infection after completion of the trial, that
sustained infection is acceptable to patients.
The hypothesis tested in this study arises from multiple
epidemiological studies demonstrating an inverse relation
between helminth infection, especially hookworm, and
both atopy and asthma [2, 3]. Previous intervention
studies relevant to this hypothesis are limited to eradica-
tion studies, mostly performed in areas where hookworm
was not the predominant endemic infection, and have
produced mixed ﬁndings. Two studies found no difference
in wheeze [16] or asthma [17] after antihelminth therapy
when compared with controls. Conversely, another study
reported a temporary improvement in asthma after alben-
dazole, although this was not statistically compared with
the placebo group [18]. Effects on atopy after antihelmith
therapy are more consistent with three studies showing a
clear increase in atopic response to allergen skin sensiti-
zation after treatment compared with controls [17, 19, 20]
with a particularly strong effect for those with both
hookworm and Ascaris infection [odds ratio (OR) 4.9,
95% CI: 1.48–16.19] [17]. However, other studies have
found the effect of antihelminth treatment when com-
pared with controls to be associated with a reduction in
atopy [19] or to have no effect [16, 21].
A number of factors may explain why our trial did not
demonstrate a statistically signiﬁcant effect on BHR. It may
be a false negative ﬁnding due to insufﬁcient statistical
power, particularly because the level of variability observed
in our primary outcome, the change in PD20AMP, was
greater than anticipated (SD 2.00 and 3.99DD in hookworm
and placebo groups, respectively). Blinding of treatment
allocation was successful for those who received placebo
and the clinical researcher who conducted the study visits
and analysed the data, but less so for participants who
received hookworm. However, we think it is unlikely that
this appreciably affected our primary outcome, because this
was based on objective measures of airway responsiveness.
There is a possibility of random error in the PD20AMP
values, and to reduce the impact of spurious results at
randomization, we used the mean of the randomization
and screening visits values to deﬁne the baseline PD20AMP,
in accordance with our protocol. We did, however, observe a
tendency for values to be higher at randomization than
screening in both groups, which we believe is most likely
due to a combination of improvement in inhaler technique
and compliance with asthma treatment following education
at the screening visit. However, we found no signiﬁcant
difference in change in PD20AMP between the groups
regardless of whether values from the screening visit,
randomization visit or the mean of the two was used as the
baseline value. While people volunteering to take part in a
study of experimental hookworm infection (or indeed any
clinical trial) may not be representative of the asthma
population in general, we have no reason to suspect that
any such differences would interact with the clinical effect
of hookworm infection.
Our previous studies showed 10 larvae to be effective in
establishing infection to an intensity producing
450eggs/g of feces [4, 6], but in the present study, eggs
were not observed at any time in feces from several
participants. Nevertheless, all infected participants exhib-
ited marked elevation of peripheral blood eosinophilia,
suggesting that those with no eggs in feces were infected
with non-fecund or same-sex organisms. It is also plau-
sible that the presence of allergic asthma reduces hook-
worm fecundity [22]. Another possibility is that the dose
administered was not adequate to induce an immunologi-
cal response of sufﬁcient strength and type to be bene-
ﬁcial. We know from our study in people with allergic
rhinoconjunctivitis that 10 infective larvae are sufﬁcient
to induce a natural immune phenotype with a weak
indication of the establishment of an immune modulatory
proﬁle [7]. However, immune modulation may require
further boosting to generate clinical beneﬁt. Boosting
could be achieved through the administration of repeated
low-dose infections or through an increase in dosage. The
former approach is probably more realistic, to avoid the
undesirable adverse effects experienced with higher doses
[4] and may mimic the pattern of natural and reportedly
beneﬁcial infection more closely. In addition, all partici-
pants in this study were receiving inhaled corticosteroid
treatment, which may have inhibited the beneﬁcial immu-
nological shift induced by worms (such as the generation of
regulatory T cell populations,) potentially conducive to
therapeutic beneﬁt and which has been linked to the
alleviation of autoimmune disease in animal models and
people with multiple sclerosis [23]. It is also possible that
our study is negative because there is no true effect of
hookworm infection in asthma, and that epidemiological
associations observed previously have arisen from bias or
confounding. However, given the consistency of the epide-
miological evidence [3], we would propose that further
studies of this hypothesis are both indicated and worth
pursuing. Finally, the epidemiological ﬁndings may arise
from reverse causation, whereby individuals with allergies
are less likely to establish hookworm infection, but the high
level of infection in our previous study, carried out in
allergic individuals, argues against this [5].
In conclusion, our work at this juncture does not prove
or refute the hypothesis that hookworm infection may
protect against asthma, but establishes that trials of this
intervention are feasible to pursue in clinical populations.
Further studies of repeated low-dose infections, with
longer periods of follow-up, and if possible, measures to
ensure greater blinding of participants, are now indicated.
Immunological monitoring for the presence of regulatory
cell populations and cytokines and further assessment of
the potential for polyclonal IgE to moderate allergic
responses, should proceed in parallel, although recent
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Hookworm as therapy for asthma 305ﬁeld work suggests that the latter mechanism may not be
operating in necatoriasis [24].
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